Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

BACKGROUND: We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola vaccination regimen in healthy and HIV-infected adults with different intervals between Ebola vaccinations. METHODS AND FINDINGS: In this randomised, observer-blind, placebo-controlled Phase II tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Barry, Houreratou, Mutua, Gaudensia, Kibuuka, Hannah, Anywaine, Zacchaeus, Sirima, Sodiomon B., Meda, Nicolas, Anzala, Omu, Eholie, Serge, Bétard, Christine, Richert, Laura, Lacabaratz, Christine, McElrath, M. Juliana, De Rosa, Stephen, Cohen, Kristen W., Shukarev, Georgi, Robinson, Cynthia, Gaddah, Auguste, Heerwegh, Dirk, Bockstal, Viki, Luhn, Kerstin, Leyssen, Maarten, Douoguih, Macaya, Thiébaut, Rodolphe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555783/
https://www.ncbi.nlm.nih.gov/pubmed/34714820
http://dx.doi.org/10.1371/journal.pmed.1003813

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555783/
https://www.ncbi.nlm.nih.gov/pubmed/34714820
http://dx.doi.org/10.1371/journal.pmed.1003813

Ejemplares similares